Medtronic (NYSE:MDT) Reaches New 52-Week High – Should You Buy?

Medtronic PLC (NYSE:MDT) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $102.80 and last traded at $102.7030, with a volume of 1416744 shares trading hands. The stock had previously closed at $101.20.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Truist Financial raised their target price on shares of Medtronic from $103.00 to $110.00 and gave the stock a “hold” rating in a research note on Thursday, November 20th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a research report on Wednesday, October 8th. Stifel Nicolaus boosted their price objective on Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. Finally, The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the company a “neutral” rating in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, Medtronic currently has an average rating of “Moderate Buy” and a consensus target price of $109.72.

Medtronic Stock Down 0.2%

The stock has a market capitalization of $134.85 billion, a price-to-earnings ratio of 28.96, a P/E/G ratio of 2.42 and a beta of 0.77. The business has a 50-day moving average of $95.46 and a 200-day moving average of $91.29. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. Medtronic’s revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.26% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Medtronic

Institutional investors and hedge funds have recently modified their holdings of the company. 1248 Management LLC purchased a new position in Medtronic in the first quarter valued at $26,000. Delos Wealth Advisors LLC acquired a new position in shares of Medtronic during the 2nd quarter worth about $27,000. Corundum Trust Company INC purchased a new position in shares of Medtronic in the 3rd quarter valued at about $27,000. Twin Tree Management LP acquired a new stake in shares of Medtronic during the 1st quarter worth about $29,000. Finally, Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic during the 3rd quarter worth about $29,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.